Ratings by Oppenheimer (Mazahir Alimohamed)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 6/22/2026 | BridgeBio Oncology Therapeutics, In | BBOT | New Coverage | Outperform (Outperform) |
7.56 (7.74) |
2.38% | Details | |
| 6/17/2026 | Tyra Biosciences | TYRA | New Coverage | Outperform (N/A) |
28.21 (29.77) |
5.53% | Details | |
| 6/10/2026 | Inhibikase Therapeutics Inc | IKT | New Coverage | Outperform (N/A) |
1.67 (1.92) |
14.97% | Details | |
| 5/20/2026 | Tarsus Pharmaceuticals | TARS | Maintain | Outperform (N/A) |
|
Details | ||
| 4/24/2026 | Tarsus Pharmaceuticals | TARS | New Coverage | Outperform (N/A) |
60.97 (60.66) |
-0.51% | Details | |
| 4/24/2026 | Inflarx NV | IFRX | New Coverage | Outperform (N/A) |
1.56 (2.40) |
53.85% | Details | |
| 4/24/2026 | Savara | SVRA | New Coverage | Outperform (N/A) |
4.94 (6.07) |
22.87% | Details | |
| 4/24/2026 | Aquestive Therapeutics | AQST | New Coverage | Outperform (N/A) |
4.07 (4.24) |
4.18% | Details |
